These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 27052)

  • 1. [Measurements and calculations on aglycon liberation from highly masked CMT selectines with beta-glucuronidase at pH 6. Realization of the principle of transport form-activity in anti-cancer drugs: theory of selectivity].
    von Ardenne M; von Ardeene A; Krüger W
    Acta Biol Med Ger; 1977; 36(9):1199-212. PubMed ID: 27052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial: Anti-cancer agents with activation in strongly hyperacidified tumor tissue: CMT selectines.
    von Ardenne M; Reitnauer PG
    Agressologie; 1976; 17(5):261-4. PubMed ID: 13670
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmacokinetic aspects of tumor tissue impairment by cancerostatics. Ways for the intensification of the induced attack in the multiple step cancer therapy. CMT-Selectine].
    von Ardenne M; von Ardenne A
    Arzneimittelforschung; 1975 Jun; 25(6):863-70. PubMed ID: 240367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interactions between desoxycholic acid glucuronides and glucuronidase (author's transl)].
    Oehlke J
    Pharmazie; 1980; 35(10):629-34. PubMed ID: 7454746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human and Escherichia coli beta-glucuronidase hydrolysis of glucuronide conjugates of benzidine and 4-aminobiphenyl, and their hydroxy metabolites.
    Zenser TV; Lakshmi VM; Davis BB
    Drug Metab Dispos; 1999 Sep; 27(9):1064-7. PubMed ID: 10460807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Constraints matrix for the concept of new cancerostatics with activation in optimally superacidulated carcinomatous tissue (author's transl)].
    Ardenne Mv; reitnauer PG
    Arch Geschwulstforsch; 1975; 45(1):34-9. PubMed ID: 239667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of beta-glucuronidase in drug disposition and drug targeting in humans.
    Sperker B; Backman JT; Kroemer HK
    Clin Pharmacokinet; 1997 Jul; 33(1):18-31. PubMed ID: 9250421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dynamics of cell proliferation.
    Moxnes JF; Haux J; Hausken K
    Med Hypotheses; 2004; 62(4):556-63. PubMed ID: 15050107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor pH-dependent toxicity of antineoplastic agents].
    Ardenne M; Reitnauer PG
    Pharmazie; 1977 Feb; 32(2):74-5. PubMed ID: 16278
    [No Abstract]   [Full Text] [Related]  

  • 11. [Screening of principal enzymes involved in the metabolism of anticancer drugs in human and murine colonic tumors].
    Massaad L; de Waziers I; Ribrag V; Janot F; Morizet J; Beaune PH; Gouyette A; Chabot GG
    Bull Cancer; 1993 May; 80(5):397-407. PubMed ID: 8173193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Principles and 1977 concept of cancer multistep therapy. Physiological fundamentals of the new timing. Selectotherm local hyperthermy (author's transl)].
    von Ardenne M
    Arch Geschwulstforsch; 1978; 48(6):504-20. PubMed ID: 31849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton transport inhibitors as potentially selective anticancer drugs.
    Harguindey S; Arranz JL; Wahl ML; Orive G; Reshkin SJ
    Anticancer Res; 2009 Jun; 29(6):2127-36. PubMed ID: 19528473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A minimal toxicity approach to cancer therapy: possible role of beta-glucuronidase.
    Rubin DM; Rubin EJ
    Med Hypotheses; 1980 Jan; 6(1):85-92. PubMed ID: 7382890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of beta-glucuronidase-resistant diastereomeric glucuronides of 3-hydroxy-3-methyloxindole formed during 3-methylindole metabolism in goats.
    Smith DJ; Appleton ML; Carlson JR; Yost GS
    Drug Metab Dispos; 1996 Jan; 24(1):119-25. PubMed ID: 8825199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
    Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
    Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucuronide transport across the endoplasmic reticulum membrane is inhibited by epigallocatechin gallate and other green tea polyphenols.
    Révész K; Tütto A; Margittai E; Bánhegyi G; Magyar JE; Mandl J; Csala M
    Int J Biochem Cell Biol; 2007; 39(5):922-30. PubMed ID: 17317271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A turning point in the knowledge of the structure-function-activity relations of elastin].
    Alix AJ
    J Soc Biol; 2001; 195(2):181-93. PubMed ID: 11727705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.